Browse > Article
http://dx.doi.org/10.5125/jkaoms.2020.46.5.341

miR-155, miR-191, and miR-494 as diagnostic biomarkers for oral squamous cell carcinoma and the effects of Avastin on these biomarkers  

Emami, Naghmeh (Department of Biology, Faculty of Basic Sciences, Islamic Azad University)
Mohamadnia, Abdolreza (Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences)
Mirzaei, Masoumeh (Department of Biology, Faculty of Basic Sciences, Islamic Azad University)
Bayat, Mohammad (Craniomaxillofacial Research Center, Tehran University of Medical Sciences)
Mohammadi, Farnoush (Craniomaxillofacial Research Center, Tehran University of Medical Sciences)
Bahrami, Naghmeh (Craniomaxillofacial Research Center, Tehran University of Medical Sciences)
Publication Information
Journal of the Korean Association of Oral and Maxillofacial Surgeons / v.46, no.5, 2020 , pp. 341-347 More about this Journal
Abstract
Objectives: Oral squamous cell carcinoma (OSCC) is one of the most common types of head and neck cancer. MicroRNAs, as new biomarkers, are recommended for diagnosis and treatment of different types of cancers. Bevacizumab, sold under the trade name Avastin, is a humanized whole monoclonal antibody that targets and blocks VEGF-A (vascular endothelial growth factor A; angiogenesis) and oncogenic signaling pathways. Materials and Methods: This study comprised 50 cases suffering from OSCC and 50 healthy participants. Peripheral blood samples were collected in glass test tubes, and RNA extraction was started immediately. Expression levels of miR-155, miR-191, and miR-494 biomarkers in the peripheral blood of OSCC-affected individuals and healthy volunteers in vivo were evaluated using real-time PCR. The influence of Avastin on the expression levels of the aforementioned biomarkers in vitro and in the HN5 cell line was also investigated. Results: Expression levels of miR-155, miR-191, and miR-494 in the peripheral blood of individuals affected by OSCC were higher than in those who were healthy. Moreover, Avastin at a concentration of 400 μM caused a decrease in the expression levels of the three biomarkers and a 1.5-fold, 3.5-fold, and 4-fold increase in apoptosis in the test samples compared to the controls in the HN5 cell line after 24, 48, and 72 hours, respectively. Conclusion: The findings of this study demonstrate that overexpression of miR-155, miR-191, and miR-494 is associated with OSCC, and Avastin is able to regulate and downregulate the expression of those biomarkers and increase apoptosis in cancerous cells in the HN5 cell line.
Keywords
Oral cancer; MicroRNA; Avastin; Real-time polymerase chain reaction; Apoptosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 2005;69 Suppl 3:46-56. https://doi.org/10.1159/000088483   DOI
2 Yoshida H, Yoshimura H, Matsuda S, Ryoke T, Kiyoshima T, Kobayashi M, et al. Effects of peritumoral bevacizumab injection against oral squamous cell carcinoma in a nude mouse xenograft model: a preliminary study. Oncol Lett 2018;15:8627-34. https://doi.org/10.3892/ol.2018.8399
3 Elyakim E, Sitbon E, Faerman A, Tabak S, Montia E, Belanis L, et al. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res 2010;70:8077-87. https://doi.org/10.1158/0008-5472.CAN-10-1313   DOI
4 Shi LJ, Zhang CY, Zhou ZT, Ma JY, Liu Y, Bao ZX, et al. MicroRNA-155 in oral squamous cell carcinoma: overexpression, localization, and prognostic potential. Head Neck 2015;37:970-6. https://doi.org/10.1002/hed.23700   DOI
5 Gissi DB, Morandi L, Gabusi A, Tarsitano A, Marchetti C, Cura F, et al. A noninvasive test for MicroRNA expression in oral squamous cell carcinoma. Int J Mol Sci 2018;19:1789. https://doi.org/10.3390/ijms19061789   DOI
6 Liborio-Kimura TN, Jung HM, Chan EK. miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. Oral Oncol 2015;51:151-7. https://doi.org/10.1016/j.oraloncology.2014.11.019   DOI
7 Zahra A, Rubab I, Malik S, Khan A, Khan MJ, Fatmi MQ. Metaanalysis of miRNAs and their involvement as biomarkers in oral cancers. Biomed Res Int 2018;2018:8439820. https://doi.org/10.1155/2018/8439820   DOI
8 Troiano G, Mastrangelo F, Caponio VCA, Laino L, Cirillo N, Lo Muzio L. Predictive prognostic value of tissue-based microRNA expression in oral squamous cell carcinoma: a systematic review and meta-analysis. J Dent Res 2018;97:759-66. https://doi.org/10.1177/0022034518762090   DOI
9 Patel RS, Jakymiw A, Yao B, Pauley BA, Carcamo WC, Katz J, et al. High resolution of microRNA signatures in human whole saliva. Arch Oral Biol 2011;56:1506-13. https://doi.org/10.1016/j.archoralbio.2011.05.015   DOI
10 Shi X, Su S, Long J, Mei B, Chen Y. MicroRNA-191 targets Ndeacetylase/N-sulfotransferase 1 and promotes cell growth in human gastric carcinoma cell line MGC803. Acta Biochim Biophys Sin (Shanghai) 2011;43:849-56. https://doi.org/10.1093/abbs/gmr084   DOI
11 Bedewy AML, Elmaghraby SM, Shehata AA, Kandil NS. Prognostic value of miRNA-155 expression in B-cell non-hodgkin lymphoma. Turk J Haematol 2017;34:207-12. https://doi.org/10.4274/tjh.2016.0286
12 Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis 2012;33:1126-33. https://doi.org/10.1093/carcin/bgs140   DOI
13 Pollutri D, Patrizi C, Marinelli S, Giovannini C, Trombetta E, Giannone FA, et al. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis 2018;9:4. https://doi.org/10.1038/s41419-017-0076-6   DOI
14 Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-802. https://doi.org/10.1016/j.clinthera.2006.11.015   DOI
15 Pang W, Su J, Wang Y, Feng H, Dai X, Yuan Y, et al. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. Cancer Sci 2015;106:1362-9. https://doi.org/10.1111/cas.12747   DOI
16 Peng WZ, Ma R, Wang F, Yu J, Liu ZB. Role of miR-191/425 cluster in tumorigenesis and diagnosis of gastric cancer. Int J Mol Sci 2014;15:4031-48. https://doi.org/10.3390/ijms15034031   DOI
17 He W, Li Y, Chen X, Lu L, Tang B, Wang Z, et al. miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol 2014;29:1427-34. https://doi.org/10.1111/jgh.12558   DOI
18 Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther 2016;1:15004. https://doi.org/10.1038/sigtrans.2015.4   DOI
19 Kumar M, Nanavati R, Modi TG, Dobariya C. Oral cancer: etiology and risk factors: a review. J Cancer Res Ther 2016;12:458-63. https://doi.org/10.4103/0973-1482.186696   DOI
20 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210   DOI
21 Nagpal N, Kulshreshtha R. miR-191: an emerging player in disease biology. Front Genet 2014;5:99. https://doi.org/10.3389/fgene.2014.00099   DOI
22 Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. Yale J Biol Med 2006;79:131-40.
23 Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012;7:e47003. https://doi.org/10.1371/journal.pone.0047003   DOI
24 Zhang X, Wu M, Chong QY, Zhang W, Qian P, Yan H, et al. Amplification of hsa-miR-191/425 locus promotes breast cancer proliferation and metastasis by targeting DICER1. Carcinogenesis 2018;39:1506-16. https://doi.org/10.1093/carcin/bgy102   DOI
25 Chen J, Nie S, Hong B, Li C, Xiong T, Shen X, et al. MicroRNA-494 promotes tumor growth by targeting PTEN in non-small cell lung cancer. Int J Clin Exp Pathol 2017;10:4441-50.
26 Qu Y, Zhang H, Sun W, Han Y, Li S, Qu Y, et al. MicroRNA-155 promotes gastric cancer growth and invasion by negatively regulating transforming growth factor-${\beta}$ receptor 2. Cancer Sci 2018;109:618-28. https://doi.org/10.1111/cas.13472   DOI
27 Chen P, Pan X, Zhao L, Jin L, Lin C, Quan J, et al. MicroRNA-191-5p exerts a tumor suppressive role in renal cell carcinoma. Exp Ther Med 2018;15:1686-93. https://doi.org/10.3892/etm.2017.5581
28 Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Lu J, et al. MicroRNA-191 promotes pancreatic cancer progression by targeting USP10. Tumour Biol 2014;35:12157-63. https://doi.org/10.1007/s13277-014-2521-9   DOI
29 Zhang XF, Li KK, Gao L, Li SZ, Chen K, Zhang JB, et al. miR-191 promotes tumorigenesis of human colorectal cancer through targeting $C/EBP{\beta}$. Oncotarget 2015;6:4144-58. https://doi.org/10.18632/oncotarget.2864   DOI
30 Colamaio M, Borbone E, Russo L, Bianco M, Federico A, Califano D, et al. miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. J Clin Endocrinol Metab 2011;96:E1915-24. https://doi.org/10.1210/jc.2011-0408   DOI
31 Macedo T, Silva-Oliveira RJ, Silva VAO, Vidal DO, Evangelista AF, Marques MMC. Overexpression of mir-183 and mir-494 promotes proliferation and migration in human breast cancer cell lines. Oncol Lett 2017;14:1054-60. https://doi.org/10.3892/ol.2017.6265   DOI
32 Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z, et al. miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN. Oncol Rep 2015;34:1003-10. https://doi.org/10.3892/or.2015.4030   DOI
33 Zhang Y, Guo L, Li Y, Feng GH, Teng F, Li W, et al. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer. Mol Cancer 2018;17:1. https://doi.org/10.1186/s12943-017-0753-1   DOI
34 Yang YK, Xi WY, Xi RX, Li JY, Li Q, Gao YE. MicroRNA-494 promotes cervical cancer proliferation through the regulation of PTEN. Oncol Rep 2015;33:2393-401. https://doi.org/10.3892/or.2015.3821   DOI
35 Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006;16:4-9. https://doi.org/10.1016/j.gde.2005.12.005   DOI
36 Yuan J, Wang K, Xi M. MiR-494 inhibits epithelial ovarian cancer growth by targeting c-Myc. Med Sci Monit 2016;22:617-24. https://doi.org/10.12659/msm.897288   DOI
37 Zhao Z, Xia G, Li N, Su R, Chen X, Zhong L. Autophagy inhibition promotes bevacizumab-induced apoptosis and proliferation inhibition in colorectal cancer cells. J Cancer 2018;9:3407-16. https://doi.org/10.7150/jca.24201   DOI
38 Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-73. https://doi.org/10.1093/annonc/mdn717   DOI
39 Zhao XM, Liu KQ, Zhu G, He F, Duval B, Richer JM, et al. Identifying cancer-related microRNAs based on gene expression data. Bioinformatics 2015;31:1226-34. https://doi.org/10.1093/bioinformatics/btu811   DOI
40 Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. microRNA therapeutics in cancer - an emerging concept. EBioMedicine 2016;12:34-42. https://doi.org/10.1016/j.ebiom.2016.09.017   DOI
41 Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002;297:2056-60. https://doi.org/10.1126/science.1073827   DOI
42 Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010;50:298-301. https://doi.org/10.1016/j.ymeth.2010.01.032   DOI
43 Xue X, Liu Y, Wang Y, Meng M, Wang K, Zang X, et al. MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget 2016;7:84508-19. https://doi.org/10.18632/oncotarget.13022   DOI
44 Lu S, Liao QS, Tang L. MiR-155 affects osteosarcoma cell proliferation and invasion through regulating $NF-{\kappa}B$ signaling pathway. Eur Rev Med Pharmacol Sci 2018;22:7633-9. https://doi.org/10.26355/eurrev_201811_16380
45 Zare A, Alipoor B, Omrani MD, Zali MR, Malekpour Alamdari N, Ghaedi H. Decreased miR-155-5p, miR-15a, and miR-186 expression in gastric cancer is associated with advanced tumor grade and metastasis. Iran Biomed J 2019;23:338-43. https://doi.org/10.29252/.23.5.338   DOI